Acciones ImmunoPrecise Antibodies Ltd. Toronto S.E.
Acciones
IPA
CA45257F2008
Farmacéuticos
Ventas 2024 * | 24,59 M 17,93 M 16,82 M | Ventas 2025 * | 29,82 M 21,75 M 20,4 M | Capitalización | 45,15 M 32,93 M 30,89 M |
---|---|---|---|---|---|
Resultado Neto 2024 * | -12 M -8,75 M -8,21 M | Resultado Neto 2025 * | -9 M -6,56 M -6,16 M | VE / Ventas 2024 * | 1,84 x |
Posición de caja neta 2024 * | - 0 0 | Posición de caja neta 2025 * | - 0 0 | VE / Ventas 2025 * | 1,51 x |
P/E ratio 2024 * |
-3,56
x | P/E ratio 2025 * |
-4,83
x | Empleados | 102 |
Rendimiento 2024 * |
-
| Rendimiento 2025 * |
-
| Flotante | 86,41 % |
Último transcript sobre ImmunoPrecise Antibodies Ltd.
Directores | Puesto | Edad | Desde |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29/09/23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/21 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05/09/23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/18 |
Varia. 1 de ene. | Capi. | |
---|---|---|
-2,68 % | 85,68 mil M | |
+5,53 % | 41,4 mil M | |
-24,99 % | 28,22 mil M | |
+55,70 % | 24,64 mil M | |
-7,19 % | 16,98 mil M | |
-34,20 % | 13,29 mil M | |
-17,31 % | 11,66 mil M | |
-11,43 % | 11,65 mil M | |
-1,80 % | 8179,07 M |